Ran Nussbaum

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Santa Monica, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Marc Panoff, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ran Nussbaum

Form 4 holding Director

UroGen Pharma Ltd.

Security class
Ordinary Shares
Shares / value
1,485,168
Estimated value
$26,747,876
Report date
21 Oct 2022
Price
$18.01
Ownership
Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd
Form 4 holding Director

LB PHARMACEUTICALS INC

Security class
Common Stock
Shares / value
1,411,681
Estimated value
Report date
12 Sep 2025
Price
Ownership
Indirect
Form 4 holding Director

Eloxx Pharmaceuticals, Inc.

Security class
Stock Options (Right to Buy)
Shares / value
20,000
Estimated value
Report date
15 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Keros Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
10,500
Estimated value
Report date
04 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

LB PHARMACEUTICALS INC

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
12 Sep 2025
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

UroGen Pharma Ltd.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
21 Oct 2022
Price
Ownership
By Pontifax Cayman III Limited Partnership
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

UroGen Pharma Ltd.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
21 Oct 2022
Price
Ownership
By Pontifax (Israel) III Limited Partnership
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by Ran Nussbaum

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .